Hydrochlorothiazide and Prevention of Kidney-Stone RecurrenceNasser A. Dhayat, Daniel G. Fuster, Urs Odermatt et al.|New England Journal of Medicine|2023Cited by 128
Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trialNasser A. Dhayat, Daniel G. Fuster, Nicolas Faller et al.|BMC Nephrology|2018Cited by 33
Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trialSimeon Schietzel, Daniel G. Fuster, Lia Bally et al.|BMJ Open|2022Cited by 31
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trialManuel Anderegg, Daniel G. Fuster, Simeon Schietzel et al.|Nature Medicine|2025Cited by 25
Nephrolithiasis secondary to inherited defects in the thick ascending loop of henle and connecting tubulesNicolas Faller, Daniel G. Fuster, Nasser A. Dhayat|Urolithiasis|2018Cited by 11